Crossmark

Metabolic-epigenetic reprogramming with low-dose metformin and valproic acid sensitizes drug-tolerant persister cells to cisplatin in gastric and liver cancer

Crossref DOI link: https://doi.org/10.1186/s40170-026-00455-0

Published Online: 2026-09-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Singh, Anjali

Natu, Abhiram

Anthony, Flevia

Lunibo, Chawang Sangchina

Karkhanis, Aishwarya

Khade, Bharat

Smoot, Duane T.

Ashktorab, Hassan

Gupta, Sanjay https://orcid.org/0000-0002-1209-189X
Funding

Funding for this research was provided by:

DAE-ACTREC (#4598)
License Information

Text and Data Mining valid from 2026-09-24

Accepted Manuscript valid from 2026-09-24
More Information

Article History

Received: 19 January 2026

Accepted: 21 August 2026

First Online: 24 September 2026

Declarations

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below